M T Yip-Schneider

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. ncbi The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer
    Christopher J Sweeney
    Department of Medicine, Indiana University School of Medicine, Indianapolis, USA
    Mol Cancer Ther 4:1004-12. 2005
  2. ncbi Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer
    Michele T Yip-Schneider
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Pancreas 42:160-7. 2013
  3. ncbi Role of 14-3-3σ in poor prognosis and in radiation and drug resistance of human pancreatic cancers
    Zhaomin Li
    Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    BMC Cancer 10:598. 2010
  4. ncbi Cyclooxygenase-2 expression in human pancreatic adenocarcinomas
    M T Yip-Schneider
    Department of Medicine, Department of Biochemistry and Walther Oncology Center, Indiana University School of Medicine, Indianapolis 46202, USA
    Carcinogenesis 21:139-46. 2000
  5. ncbi Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells
    Michele T Yip-Schneider
    Department of Surgery, Indiana University School of Medicine, Room 041, Building R4, 1044 West Walnut Street, Indianapolis, IN 46202, USA
    Mol Cancer Ther 4:587-94. 2005
  6. ncbi Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer
    Michele T Yip-Schneider
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA
    Pancreas 37:e45-53. 2008
  7. ncbi Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo
    Michele T Yip-Schneider
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Mol Cancer Ther 6:1736-44. 2007
  8. ncbi Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2
    M T Yip-Schneider
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, 46202, USA
    Biochem Biophys Res Commun 280:992-7. 2001
  9. ncbi Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells
    M T Yip-Schneider
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    J Pharmacol Exp Ther 298:976-85. 2001
  10. ncbi NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4
    Gregory Helbig
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Biol Chem 278:21631-8. 2003

Collaborators

Detail Information

Publications50

  1. ncbi The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer
    Christopher J Sweeney
    Department of Medicine, Indiana University School of Medicine, Indianapolis, USA
    Mol Cancer Ther 4:1004-12. 2005
    ..These results for the first time reveal the significant in vivo chemosensitizing properties of parthenolide in the metastatic breast cancer setting and support the contention that metastases are very reliant on activation of NF-kappaB...
  2. ncbi Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer
    Michele T Yip-Schneider
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Pancreas 42:160-7. 2013
    ..Gemcitabine, traditionally a chemotherapeutic agent, has relatively low toxicity; thus, combinations with low-dose gemcitabine were also explored...
  3. ncbi Role of 14-3-3σ in poor prognosis and in radiation and drug resistance of human pancreatic cancers
    Zhaomin Li
    Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    BMC Cancer 10:598. 2010
    ..Recently, the level of 14-3-3σ mRNA was found to be increased in pancreatic cancers and this increased expression may contribute to the failure in treatment of pancreatic cancers. In the present study, we tested this hypothesis...
  4. ncbi Cyclooxygenase-2 expression in human pancreatic adenocarcinomas
    M T Yip-Schneider
    Department of Medicine, Department of Biochemistry and Walther Oncology Center, Indiana University School of Medicine, Indianapolis 46202, USA
    Carcinogenesis 21:139-46. 2000
    ..Taken together, our data suggest that COX-2 may play an important role in pancreatic tumorigenesis and therefore be a promising chemotherapeutic target for the treatment of pancreatic cancer...
  5. ncbi Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells
    Michele T Yip-Schneider
    Department of Surgery, Indiana University School of Medicine, Room 041, Building R4, 1044 West Walnut Street, Indianapolis, IN 46202, USA
    Mol Cancer Ther 4:587-94. 2005
    ..These data provide preclinical support for a combined chemotherapeutic approach with NF-kappa B inhibitors and NSAIDs for the treatment of pancreatic adenocarcinoma...
  6. ncbi Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer
    Michele T Yip-Schneider
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA
    Pancreas 37:e45-53. 2008
    ..The efficacy of a novel bioavailable anticancer agent, dimethylamino-parthenolide (DMAPT), and the cyclooxygenase 2 inhibitor, celecoxib, was evaluated in a carcinogen-induced developmental model of pancreatic cancer...
  7. ncbi Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo
    Michele T Yip-Schneider
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Mol Cancer Ther 6:1736-44. 2007
    ..These results suggest that LC-1 and sulindac may mediate their antitumor effects, in part, by altering cyclin D1 levels. Furthermore, this study provides preclinical evidence for the therapeutic efficacy of these agents...
  8. ncbi Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2
    M T Yip-Schneider
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, 46202, USA
    Biochem Biophys Res Commun 280:992-7. 2001
    ..Taken together, these results suggest that pancreatic tumor cells expressing oncogenic K-ras compensate, in part, by upregulating the expression of MKP-2 to repress the ERK signaling pathway...
  9. ncbi Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells
    M T Yip-Schneider
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    J Pharmacol Exp Ther 298:976-85. 2001
    ..In addition, NSAIDs in combination with gemcitabine may hold promise in the clinic for the treatment of pancreatic cancer...
  10. ncbi NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4
    Gregory Helbig
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Biol Chem 278:21631-8. 2003
    ..Taken together, these results implicate NF-kappaB in the migration and the organ-specific homing of metastatic breast cancer cells...
  11. ncbi Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase
    Minghai Shao
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Cancer Res 69:9192-201. 2009
    ..Highly expressed in ovarian tumors, TG2 promotes EMT and enhances ovarian tumor metastasis by activating oncogenic signaling...
  12. ncbi Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model
    Rajasubramaniam Shanmugam
    Department of Medicine, Indiana University, Indianapolis, Indiana, USA
    Prostate 66:1498-511. 2006
    ..CONCLUSION: These studies demonstrate parthenolide's anti-tumor and anti-angiogenic activity, and its potential to augment the efficacy of chemotherapy and hormonal therapy...
  13. ncbi The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1alpha/CXCL12
    Hiromitsu Kishimoto
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Carcinogenesis 26:1706-15. 2005
    ..These results also provide a molecular explanation for recent observations linking co-overexpression of coactivators and her2/neu with poor prognosis: coactivators increase SDF-1alpha expression whereas her2/neu stabilize CXCR4 protein...
  14. ncbi Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet
    Kasi McCune
    Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Cancer Res 70:685-96. 2010
    ....
  15. ncbi FOXA1 expression in breast cancer--correlation with luminal subtype A and survival
    Sunil Badve
    Department of Pathology, Indiana University School of Medicine, Indianapolis, USA
    Clin Cancer Res 13:4415-21. 2007
    ..It segregates with genes that characterize the luminal subtypes in DNA microarray analyses. The utility of FOXA1 as a possible independent prognostic factor has not been determined in breast cancers...
  16. ncbi Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling
    Liyun Cao
    Department of Medicine, Richard L Roudebush Veterans Affairs Medical Center, Indiana University School of Medicine, 535 Barnhill Drive, RT 473, Indianapolis, IN 46202, USA
    Carcinogenesis 29:1893-900. 2008
    ..Our data show that TG2 prevents apoptosis induced by cisplatin by activating the NF-kappaB survival pathway in ovarian cancer cells...
  17. ncbi Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer
    Anjaiah Srirangam
    Department of Medicine, Indiana University, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 12:1883-96. 2006
    ..Ritonavir may be of interest for breast cancer therapeutics and its efficacy may be increased by sustained exposure or Hsp90 RNA interference...
  18. ncbi Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells
    Poornima Bhat-Nakshatri
    Walther Oncology Center, Indiana University School of Medicine, Indianapolis, Indiana, IN 46202, USA
    Oncogene 21:2066-78. 2002
    ....
  19. ncbi A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species
    Rajasubramaniam Shanmugam
    Department of Medicine, Indiana University, Indianapolis, Indiana, USA
    Prostate 70:1074-86. 2010
    ..To characterize the molecular changes associated with DMAPT-induced prostate cancer cell death and its in vivo activity...
  20. ncbi NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy
    Jian Min Wu
    Department of Surgery, Indiana University School of Medicine, 1001 W 10th Street, Indianapolis, IN 46202, USA
    Cancer Lett 278:145-55. 2009
    ....
  21. ncbi Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer
    Suresh Kumar
    Departments of Surgery, Indiana University School of Medicine, Indianapolis 46202, USA
    Am J Pathol 163:2531-41. 2003
    ..Taken together, these results suggest that cancer cell-derived cytokines, such as IL-1 alpha, induce cachexia by affecting leptin-dependent metabolic pathways...
  22. ncbi Breast cancer stem cells and intrinsic subtypes: controversies rage on
    Harikrishna Nakshatri
    Department of Surgery, Indiana University School of Medicine, 1044 West Walnut Street, Indianapolis, IN 46202, USA
    Curr Stem Cell Res Ther 4:50-60. 2009
    ....
  23. ncbi AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer
    Poornima Bhat-Nakshatri
    Department of Surgery, Indiana University School of Medicine, 1044 West Walnut St, Indianapolis, IN 46202, USA
    Mol Cell Biol 28:7487-503. 2008
    ....
  24. ncbi FOXA1 in breast cancer
    Harikrishna Nakshatri
    Departments of Surgery, Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Expert Rev Mol Med 11:e8. 2009
    ..Additionally, we discuss modulators of FOXA1 function, ERalpha-FOXA1-GATA3 downstream targets, and potential therapeutic agents that may increase differentiation through FOXA1...
  25. ncbi Intrinsic subtype-associated changes in the plasma proteome in breast cancer
    Harikrishna Nakshatri
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA
    Proteomics Clin Appl 3:1305-13. 2009
    ..These results reveal intrinsic subtype specific changes in the plasma proteome that may influence tumor progression as well as the systemic effects of cancer...
  26. ncbi Obesity potentiates the growth and dissemination of pancreatic cancer
    Nicholas J Zyromski
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Surgery 146:258-63. 2009
    ..The aim of the current study was to investigate the influence of obesity on pancreatic cancer growth using a novel in vivo model...
  27. ncbi Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications
    Sunil Badve
    Department of Pathology and Internal Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Am J Pathol 176:2139-49. 2010
    ..These results suggest that subcellular localization of activated AKT plays a significant role in determining its function in breast cancer, which in part is dependent on TCL1B expression...
  28. ncbi Antimyeloma effects of a sesquiterpene lactone parthenolide
    Attaya Suvannasankha
    Hematology and Oncology Division, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 14:1814-22. 2008
    ..The sesquiterpene lactone parthenolide targets NF-kappaB. However, its therapeutic potential in MM is not known...
  29. ncbi NF-kappaB and breast cancer
    Harikrishna Nakshatri
    Indiana University School of Medicine, Walther Cancer Institute, Indianapolis, USA
    Curr Probl Cancer 26:282-309. 2002
  30. ncbi Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel
    Zhuo Wang
    Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Anticancer Res 25:2367-79. 2005
    ....
  31. ncbi Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase
    Harikrishna Nakshatri
    Department of Surgery, Indiana University School of Medicine, Indianapolis 46202, USA
    Oncogene 23:7330-44. 2004
    ..These results identify a new antitumor activity of parthenolide, which can be exploited to reverse resistance of cancer cells to TRAIL, particularly those with elevated XIAP levels...
  32. ncbi The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells
    Daniela Matei
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    J Biol Chem 282:445-53. 2007
    ..These results show that 17-AAG promotes PDGFRalpha degradation selectively in transformed cells. Thus, not only mutated tyrosine kinases but also overexpressed receptors in cancer cells can be targeted by 17-AAG...
  33. ncbi Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation
    Meiyun Fan
    Medical Sciences, Indiana University School of Medicine, 302 Jordan Hall, 1001 East 3rd Street, Bloomington, Indiana 47405-4401, USA
    Mol Endocrinol 18:2603-15. 2004
    ....
  34. ncbi FOXA1 as a therapeutic target for breast cancer
    Harikrishna Nakshatri
    Indiana University School of Medicine, Departments of Surgery, Biochemistry and Molecular Biology, Walther Oncology Center, Indianapolis, IN 46202, USA
    Expert Opin Ther Targets 11:507-14. 2007
    ..This article reviews possible roles of FOXA family transcription factors in breast cancer initiation, hormone dependency and speculates on the potential of FOXA1 as a therapeutic target...
  35. ncbi Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-kappaB and split-dose repair
    Marc S Mendonca
    Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Radiat Res 168:689-97. 2007
    ..Further studies demonstrated that the enhancement of X-ray-induced cell killing by parthenolide is due to inhibition of split-dose repair...
  36. ncbi Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate
    Christopher Sweeney
    Department of Medicine, Indiana University, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 10:5501-7. 2004
    ..The transcription factor nuclear factor-kappaB (NF-kappaB) promotes the production of angiogenic, antiapoptotic, and prometastatic factors that are involved in carcinogenesis...
  37. ncbi Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase
    Minati Satpathy
    Department of Medicine, Indiana University School of Medicine, 535 Barnhill Drive, RT 473, Indianapolis, IN 46202, USA
    Cancer Res 67:7194-202. 2007
    ..Highly expressed in ovarian tumors, TG2 facilitates i.p. tumor dissemination by enhancing cell adhesion to the extracellular matrix and modulating beta(1) integrin subunit expression...
  38. ncbi Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores
    Foluso O Ademuyiwa
    Department of Medicine, Indiana University, School of Medicine, Indianapolis, IN 46202, USA
    Mod Pathol 23:270-5. 2010
    ..To confirm these findings, further studies in a larger cohort of patients are warranted...
  39. ncbi Estradiol-regulated microRNAs control estradiol response in breast cancer cells
    Poornima Bhat-Nakshatri
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA
    Nucleic Acids Res 37:4850-61. 2009
    ..Additionally, our studies reveal a negative-regulatory loop controlling E2 response through microRNAs as well as differences in E2-induced transcriptome and proteome...
  40. ncbi CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis
    Carol Sheridan
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Breast Cancer Res 8:R59. 2006
    ..CONCLUSION: Breast cancer cells with CD44+/CD24- subpopulation express higher levels of proinvasive genes and have highly invasive properties. However, this phenotype is not sufficient to predict capacity for pulmonary metastasis...
  41. ncbi Striatin-3 gamma inhibits estrogen receptor activity by recruiting a protein phosphatase
    Bailin Tan
    Department of Obstetrics and Gynecology University School of Medicine, Indianapolis, Indiana 46202, USA
    J Mol Endocrinol 40:199-210. 2008
    ..These observations suggest that an rSTRN3gamma-PP2A(C) complex is recruited to agonist-activated ERalpha, thereby leading to its dephosphorylation and inhibiting transcription...
  42. ncbi Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer
    Reid C Vegeler
    Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    J Surg Res 143:169-76. 2007
    ..The therapeutic potential of celecoxib, a COX-2 selective inhibitor, and LC-1, a pro-apoptotic drug with accompanying inhibition of NF-kappaB, were investigated...
  43. ncbi MOZ and MOZ-CBP cooperate with NF-kappaB to activate transcription from NF-kappaB-dependent promoters
    Edward M Chan
    Walther Oncology Center, Indianapolis, IN, USA
    Exp Hematol 35:1782-92. 2007
    ....
  44. ncbi The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells
    Wyatt Wollmann
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Carcinogenesis 26:900-7. 2005
    ..These results suggest that AKT/PKB through MIC-1 could regulate the ERK1 activity and the MIC-1 expression levels may serve as a surrogate marker for the AKT activation in tumors...
  45. ncbi Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer
    Eardie A Curry
    Department of Pharmacy Practice, Purdue University, Indianapolis, IN, USA
    Invest New Drugs 22:299-305. 2004
    ..Purification of parthenolide for administration of higher doses will be needed...
  46. ncbi Negative regulation of MHC class II gene expression by CXCR4
    Carol Sheridan
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Exp Hematol 34:1085-92. 2006
    ..We have initiated a study aimed at dissecting additional functions of CXCR4 in cancer cells, particularly in relation to the immune system...
  47. ncbi MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac
    Michele T Yip-Schneider
    Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Pancreas 27:337-44. 2003
    ..In addition, we investigated whether the MEK-ERK pathway influenced the response of pancreatic cancer cells to nonsteroidal antiinflammatory drugs (NSAIDs)...
  48. ncbi 2-methoxyestradiol inhibits the anaphase-promoting complex and protein translation in human breast cancer cells
    Rajendra Bhati
    Lineberger Comprehensive Cancer Center, Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Cancer Res 67:702-8. 2007
    ..2ME2 induces tubulin-dependent cell cycle arrest through regulation of genes involved in the mitotic spindle assembly checkpoint, which results in inhibition of the APC and tubulin-independent inhibition of protein translation...
  49. ncbi Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover
    Nagendra K Prasad
    Department of Basic Medical Sciences and Purdue Cancer Center, Purdue University, Lynn Hall, 625 Harrison Street, West Lafayette, IN 47907, USA
    Carcinogenesis 29:25-34. 2008
    ..Taken together, our results demonstrate that SHIP2 is a clinically relevant novel anticancer target that links perturbed metabolism to cancer development...
  50. ncbi Identity profiling of cell surface markers by multiplex gold nanorod probes
    Chenxu Yu
    Department of Agricultural and Biological Engineering and Bindley Biosciences Center, Purdue University, 225 South University Drive, West Lafayette, Indiana 47906, USA
    Nano Lett 7:2300-6. 2007
    ..The technique has the potential to become an important tool for diagnosis and prognosis of breast and other cancers...